Financial metrics for LENZ Therapeutics reflect its recent transition from a clinical-stage research enterprise into a commercial-stage pharmaceutical firm scaling its product launch. While the company incurs ongoing operational expenses and research investments associated with commercial sales infrastructure, its balance sheet is managed to support the market rollout of VIZZ, backed by capital allocations from public equity offerings and institutional funding.